Scholarlink

Background <p>Severe neonatal episodic laryngospasm has been previously reported in multiple patients with the heterozygous pathogenic variant G1306E in <i>SCN4A</i>. Treatment can be difficult due to side effects from therapies utilized conventionally for the management of myotonia and paramyotonia congenita.</p> Case presentation <p>We report on two female siblings of Irish, Scandinavian, and German ethnicity aged 7 and 3&#xa0;years with severe neonatal episodic laryngospasm and paramyotonia congenita due to a paternally inherited heterozygous pathogenic variant of the <i>SCN4A</i> gene and the use of high-dose flecainide therapy for symptomatic management. Interestingly, one of the two siblings has a coexisting separate maternally inherited and pathogenic <i>CLCN1</i> variant that may further impact phenotype. High-dose flecainide 220–250&#xa0;mg/m<sup>2</sup>/day was not associated with any cardiac side effects.</p> Conclusion <p>This report supports the use of high-dose flecainide in combination with standard therapies in pediatric patients with <i>SCN4A</i> mutations to modulate acute symptoms and provides suggested dosing with an acute and long-term monitoring protocol.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High-dose flecainide for symptomatic relief in paramyotonia congenita/severe neonatal episodic laryngospasm due to SCN4A G1306E: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月13日

查看全文
  • Vanessa Ogueri,
  • Jessica Chong,
  • Melissa Fleming,
  • Kara Simpson,
  • Elizabeth Sherwin,
  • Diana Bharucha-Goebel,
  • Christopher Spurney

摘要

Background

Severe neonatal episodic laryngospasm has been previously reported in multiple patients with the heterozygous pathogenic variant G1306E in SCN4A. Treatment can be difficult due to side effects from therapies utilized conventionally for the management of myotonia and paramyotonia congenita.

Case presentation

We report on two female siblings of Irish, Scandinavian, and German ethnicity aged 7 and 3 years with severe neonatal episodic laryngospasm and paramyotonia congenita due to a paternally inherited heterozygous pathogenic variant of the SCN4A gene and the use of high-dose flecainide therapy for symptomatic management. Interestingly, one of the two siblings has a coexisting separate maternally inherited and pathogenic CLCN1 variant that may further impact phenotype. High-dose flecainide 220–250 mg/m2/day was not associated with any cardiac side effects.

Conclusion

This report supports the use of high-dose flecainide in combination with standard therapies in pediatric patients with SCN4A mutations to modulate acute symptoms and provides suggested dosing with an acute and long-term monitoring protocol.